ALEC
Alector, Inc.
Price Chart
Latest Quote
$1.64
-0.18 (-9.67%)
Current Price
| Previous Close | $1.81 |
| Open | $1.84 |
| Day High | $1.84 |
| Day Low | $1.62 |
| Volume | 362,980 |
Stock Information
| Shares Outstanding | 111.03M |
| Total Debt | $34.55M |
| Cash Equivalents | $206.52M |
| Revenue | $18.42M |
| Net Income | $-125.39M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $181.53M |
| EPS (TTM) | $-1.19 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $9.56M |
| Sales | $18.42M |
| Income | $-125.39M |
| Book/sh | $0.09 |
| Cash/sh | $1.86 |
| Employees | 103 |
Financial Ratios
| Quick Ratio | 5.04 |
| Current Ratio | 5.25 |
| Debt/Eq | 332.77 |
Returns & Margins
| ROA | -25.71% |
| ROE | -238.85% |
| Operating Margin | -2382.31% |
Ownership
| Insider Ownership | 9.46% |
| Institutional Ownership | 82.26% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.34 |
| P/S | 9.86 |
| P/B | 17.39 |
Analyst Data
| Recommendation | none |
| Target Price | $3.10 |
Technical Indicators
| SMA20 | $2.08 |
| SMA50 | $2.27 |
| SMA200 | $2.11 |
| RSI | 19.30 |
| ATR | 0.1586 |
| Shares Float | 94.09M |
| Short Float | 4.63% |
| Short Ratio | 9.35 |
| Volatility | 0.59 |
| Rel Volume | 0.47 |
Performance History
| Week | -24.31% |
| Month | -36.38% |
| Quarter | -18.25% |
| 6 Months | +43.42% |
| YTD | +6.86% |
| Year | +5.48% |
| 3 Years | -78.02% |
| 5 Years | -90.81% |
| 10 Years | -90.96% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $1.63 | 364,300 |
| 2026-06-04 | $1.81 | 449,400 |
| 2026-06-03 | $1.77 | 1,691,700 |
| 2026-06-02 | $1.95 | 1,561,000 |
| 2026-06-01 | $2.07 | 705,800 |
| 2026-05-29 | $2.16 | 993,200 |
| 2026-05-28 | $2.15 | 1,300,400 |
| 2026-05-27 | $2.21 | 462,400 |
| 2026-05-26 | $2.19 | 480,600 |
| 2026-05-22 | $2.21 | 328,100 |
| 2026-05-21 | $2.21 | 929,700 |
| 2026-05-20 | $2.12 | 898,500 |
| 2026-05-19 | $2.11 | 790,400 |
| 2026-05-18 | $2.12 | 814,500 |
| 2026-05-15 | $2.16 | 1,104,600 |
| 2026-05-14 | $2.30 | 783,200 |
| 2026-05-13 | $2.15 | 459,100 |
| 2026-05-12 | $2.16 | 437,300 |
| 2026-05-11 | $2.05 | 389,100 |
| 2026-05-08 | $2.10 | 720,500 |
| 2026-05-07 | $2.44 | 276,500 |
| 2026-05-06 | $2.57 | 470,600 |
About Alector, Inc.
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
đ° Latest News
How The Alector (ALEC) Investment Story Is Shifting With Tau Readthroughs And BBB Shuttle Focus
Simply Wall St. âĸ 2026-05-19T04:34:16Z
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-07T23:05:08Z
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Zacks âĸ 2026-05-07T14:00:07Z
Alkermes (ALKS) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-05T12:25:02Z
GSK Juggles Alzheimerâs Setback And Leadership Shift With Product Progress
Simply Wall St. âĸ 2026-05-03T01:19:00Z
How The Alector (ALEC) Narrative Is Shifting Toward BBB Shuttle Programs And Execution Risk
Simply Wall St. âĸ 2026-04-30T12:08:49Z
Discovering Middle East's Undiscovered Gems This April 2026
Simply Wall St. âĸ 2026-04-28T03:33:11Z
Undiscovered Gems in the Middle East for March 2026
Simply Wall St. âĸ 2026-03-26T08:33:23Z
Why The Narrative Around Alector (ALEC) Is Shifting With Its BBB Shuttle Focus
Simply Wall St. âĸ 2026-03-20T23:04:46Z
Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles
24/7 Wall St. âĸ 2026-03-10T14:09:45Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $21,045,000 | $100,558,000 | $97,062,000 | $133,617,000 |
| Operating Revenue | $21,045,000 | $100,558,000 | $97,062,000 | $133,617,000 |
| Expenses | ||||
| Total Expenses | $177,052,000 | $245,555,000 | $248,802,000 | $271,451,000 |
| Other Income Expense | $13,246,000 | $26,076,000 | $26,561,000 | $7,778,000 |
| Other Non Operating Income Expenses | $13,246,000 | $26,076,000 | $26,561,000 | $7,778,000 |
| Operating Expense | $177,052,000 | $245,555,000 | $248,802,000 | $271,451,000 |
| General And Administrative Expense | $53,987,000 | $59,615,000 | $56,687,000 | $61,033,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-142,929,000 | $-119,049,000 | $-130,391,000 | $-133,310,000 |
| Normalized Income | $-142,929,000 | $-119,049,000 | $-130,391,000 | $-133,310,000 |
| Net Income From Continuing And Discontinued Operation | $-142,929,000 | $-119,049,000 | $-130,391,000 | $-133,310,000 |
| Total Operating Income As Reported | $-156,007,000 | $-144,997,000 | $-151,740,000 | $-137,834,000 |
| Net Income Common Stockholders | $-142,929,000 | $-119,049,000 | $-130,391,000 | $-133,310,000 |
| Net Income | $-142,929,000 | $-119,049,000 | $-130,391,000 | $-133,310,000 |
| Net Income Including Noncontrolling Interests | $-142,929,000 | $-119,049,000 | $-130,391,000 | $-133,310,000 |
| Net Income Continuous Operations | $-142,929,000 | $-119,049,000 | $-130,391,000 | $-133,310,000 |
| Pretax Income | $-142,761,000 | $-118,921,000 | $-125,179,000 | $-130,056,000 |
| Operating Income | $-156,007,000 | $-144,997,000 | $-151,740,000 | $-137,834,000 |
| Per Share | ||||
| Diluted EPS | $-1.39 | $-1.23 | $-1.56 | $-1.62 |
| Basic EPS | $-1.39 | $-1.23 | $-1.56 | $-1.62 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-146,346,000 | $-136,156,000 | $-142,892,000 | $-129,362,000 |
| Reconciled Depreciation | $9,661,000 | $8,841,000 | $8,848,000 | $8,472,000 |
| EBITDA (Bullshit earnings) | $-146,346,000 | $-136,156,000 | $-142,892,000 | $-129,362,000 |
| EBIT | $-156,007,000 | $-144,997,000 | $-151,740,000 | $-137,834,000 |
| Diluted Average Shares | $102,998,978 | $96,588,177 | $83,733,730 | $82,467,587 |
| Basic Average Shares | $102,998,978 | $96,588,177 | $83,733,730 | $82,467,587 |
| Diluted NI Availto Com Stockholders | $-142,929,000 | $-119,049,000 | $-130,391,000 | $-133,310,000 |
| Tax Provision | $168,000 | $128,000 | $5,212,000 | $3,254,000 |
| Research And Development | $123,065,000 | $185,940,000 | $192,115,000 | $210,418,000 |
| Selling General And Administration | $53,987,000 | $59,615,000 | $56,687,000 | $61,033,000 |
| Other Gand A | $53,987,000 | $59,615,000 | $56,687,000 | $61,033,000 |
Fetched: 2026-05-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $30,649,000 | $126,800,000 | $134,158,000 | $214,442,000 |
| Total Assets | $293,237,000 | $468,303,000 | $621,827,000 | $787,648,000 |
| Total Non Current Assets | $26,785,000 | $43,486,000 | $56,020,000 | $61,213,000 |
| Other Non Current Assets | $2,232,000 | $6,390,000 | $8,964,000 | $7,881,000 |
| Current Assets | $266,452,000 | $424,817,000 | $565,807,000 | $726,435,000 |
| Other Current Assets | $10,428,000 | $11,420,000 | $16,946,000 | $10,997,000 |
| Cash Cash Equivalents And Short Term Investments | $256,024,000 | $413,397,000 | $548,861,000 | $712,851,000 |
| Cash And Cash Equivalents | $65,802,000 | $33,021,000 | $74,555,000 | $154,323,000 |
| Receivables | - | - | $0 | $2,587,000 |
| Prepaid Assets | - | - | - | $10,997,000 |
| Debt | ||||
| Total Debt | $36,233,000 | $42,519,000 | $38,918,000 | $43,327,000 |
| Long Term Debt And Capital Lease Obligation | $26,811,000 | $33,765,000 | $30,456,000 | $35,268,000 |
| Long Term Debt | $9,323,000 | $9,389,000 | - | - |
| Current Debt And Capital Lease Obligation | $9,422,000 | $8,754,000 | $8,462,000 | $8,059,000 |
| Current Debt | $366,000 | - | - | - |
| Other Current Borrowings | $366,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $262,588,000 | $341,503,000 | $487,669,000 | $573,206,000 |
| Total Non Current Liabilities Net Minority Interest | $193,085,000 | $216,444,000 | $309,721,000 | $479,397,000 |
| Other Non Current Liabilities | $1,737,000 | $1,234,000 | $1,373,000 | $759,000 |
| Non Current Deferred Liabilities | $164,537,000 | $172,169,000 | $210,845,000 | $443,370,000 |
| Current Liabilities | $69,503,000 | $125,059,000 | $177,948,000 | $93,809,000 |
| Current Deferred Liabilities | $6,684,000 | $23,663,000 | $82,975,000 | $48,231,000 |
| Payables And Accrued Expenses | $29,007,000 | $25,795,000 | $31,774,000 | $24,761,000 |
| Payables | $18,980,000 | $8,129,000 | $11,478,000 | $4,189,000 |
| Other Payable | $17,289,000 | $5,914,000 | $7,703,000 | - |
| Accounts Payable | $1,691,000 | $2,215,000 | $3,775,000 | $4,189,000 |
| Equity | ||||
| Common Stock Equity | $30,649,000 | $126,800,000 | $134,158,000 | $214,442,000 |
| Total Equity Gross Minority Interest | $30,649,000 | $126,800,000 | $134,158,000 | $214,442,000 |
| Stockholders Equity | $30,649,000 | $126,800,000 | $134,158,000 | $214,442,000 |
| Gains Losses Not Affecting Retained Earnings | $166,000 | $261,000 | $184,000 | $-4,575,000 |
| Other Equity Adjustments | $166,000 | $261,000 | $184,000 | $-4,575,000 |
| Retained Earnings | $-972,056,000 | $-829,127,000 | $-710,078,000 | $-579,687,000 |
| Other | ||||
| Ordinary Shares Number | $110,362,581 | $99,085,888 | $84,879,693 | $82,895,718 |
| Share Issued | $110,362,581 | $99,085,888 | $84,879,693 | $82,895,718 |
| Tangible Book Value | $30,649,000 | $126,800,000 | $134,158,000 | $214,442,000 |
| Invested Capital | $40,338,000 | $136,189,000 | $134,158,000 | $214,442,000 |
| Working Capital | $196,949,000 | $299,758,000 | $387,859,000 | $632,626,000 |
| Capital Lease Obligations | $26,544,000 | $33,130,000 | $38,918,000 | $43,327,000 |
| Total Capitalization | $39,972,000 | $136,189,000 | $134,158,000 | $214,442,000 |
| Additional Paid In Capital | $1,002,528,000 | $955,657,000 | $844,044,000 | $798,696,000 |
| Capital Stock | $11,000 | $9,000 | $8,000 | $8,000 |
| Common Stock | $11,000 | $9,000 | $8,000 | $8,000 |
| Non Current Deferred Revenue | $164,537,000 | $172,169,000 | $210,845,000 | $443,370,000 |
| Long Term Capital Lease Obligation | $17,488,000 | $24,376,000 | $30,456,000 | $35,268,000 |
| Current Deferred Revenue | $6,684,000 | $23,663,000 | $82,975,000 | $48,231,000 |
| Current Capital Lease Obligation | $9,056,000 | $8,754,000 | $8,462,000 | $8,059,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $12,941,000 | $18,213,000 | $15,297,000 | $12,758,000 |
| Current Provisions | $11,449,000 | $48,634,000 | $39,440,000 | - |
| Current Accrued Expenses | $10,027,000 | $17,666,000 | $20,296,000 | $20,572,000 |
| Net PPE | $24,553,000 | $37,096,000 | $47,056,000 | $53,332,000 |
| Accumulated Depreciation | $-37,493,000 | $-32,942,000 | $-28,050,000 | $-22,612,000 |
| Gross PPE | $62,046,000 | $70,038,000 | $75,106,000 | $75,944,000 |
| Leases | $24,942,000 | $26,357,000 | $26,616,000 | $26,228,000 |
| Other Properties | $32,258,000 | $38,835,000 | $43,688,000 | $44,976,000 |
| Machinery Furniture Equipment | $4,846,000 | $4,846,000 | $4,802,000 | $4,740,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $190,222,000 | $380,376,000 | $474,306,000 | $558,528,000 |
| Long Term Provisions | - | $9,276,000 | $67,047,000 | - |
| Duefrom Related Parties Current | - | - | $0 | $2,587,000 |
Fetched: 2026-05-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-184,072,000 | $-231,160,000 | $-186,543,000 | $-24,446,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-184,031,000 | $-229,905,000 | $-184,162,000 | $-20,329,000 |
| Cash Flow From Continuing Operating Activities | $-184,031,000 | $-229,905,000 | $-184,162,000 | $-20,329,000 |
| Operating Gains Losses | - | - | $48,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-41,000 | $-1,255,000 | $-2,381,000 | $-4,117,000 |
| Investing Cash Flow | $196,597,000 | $107,131,000 | $101,918,000 | $-159,014,000 |
| Cash Flow From Continuing Investing Activities | $196,597,000 | $107,131,000 | $101,918,000 | $-159,014,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $19,983,000 | $71,108,000 | $0 | $0 |
| Financing Cash Flow | $20,215,000 | $81,540,000 | $2,550,000 | $4,514,000 |
| Cash Flow From Continuing Financing Activities | $20,215,000 | $81,540,000 | $2,550,000 | $4,514,000 |
| Net Common Stock Issuance | $19,983,000 | $71,108,000 | $0 | $0 |
| Common Stock Issuance | $19,983,000 | $71,108,000 | $0 | $0 |
| Other | ||||
| Issuance Of Debt | $0 | $9,389,000 | $0 | $0 |
| Interest Paid Supplemental Data | $855,000 | $0 | - | - |
| End Cash Position | $67,648,000 | $34,867,000 | $76,101,000 | $155,795,000 |
| Beginning Cash Position | $34,867,000 | $76,101,000 | $155,795,000 | $330,624,000 |
| Changes In Cash | $32,781,000 | $-41,234,000 | $-79,694,000 | $-174,829,000 |
| Proceeds From Stock Option Exercised | $232,000 | $1,043,000 | $2,550,000 | $4,514,000 |
| Net Issuance Payments Of Debt | $0 | $9,389,000 | $0 | $0 |
| Net Long Term Debt Issuance | $0 | $9,389,000 | $0 | $0 |
| Long Term Debt Issuance | $0 | $9,389,000 | $0 | $0 |
| Net Investment Purchase And Sale | $196,638,000 | $108,386,000 | $104,299,000 | $-154,897,000 |
| Sale Of Investment | $468,517,000 | $576,127,000 | $656,028,000 | $402,001,000 |
| Purchase Of Investment | $-271,879,000 | $-467,741,000 | $-551,729,000 | $-556,898,000 |
| Net PPE Purchase And Sale | $-41,000 | $-1,255,000 | $-2,381,000 | $-4,117,000 |
| Purchase Of PPE | $-41,000 | $-1,255,000 | $-2,381,000 | $-4,117,000 |
| Change In Working Capital | $-74,057,000 | $-146,986,000 | $-90,147,000 | $59,526,000 |
| Change In Other Working Capital | $-21,045,000 | $-100,558,000 | $-66,782,000 | $66,383,000 |
| Change In Other Current Liabilities | $-56,109,000 | $-51,938,000 | $-28,866,000 | $-3,673,000 |
| Change In Other Current Assets | $4,158,000 | $2,874,000 | $-1,009,000 | $-835,000 |
| Change In Payables And Accrued Expense | $-2,053,000 | $-2,890,000 | $9,872,000 | $-3,227,000 |
| Change In Accrued Expense | $-12,904,000 | $340,000 | $2,546,000 | $-2,655,000 |
| Change In Payable | $10,851,000 | $-3,230,000 | $7,326,000 | $-572,000 |
| Change In Account Payable | $-524,000 | $-1,441,000 | $-377,000 | $-572,000 |
| Change In Prepaid Assets | $992,000 | $5,526,000 | $-5,949,000 | $-3,926,000 |
| Other Non Cash Items | $293,000 | - | - | - |
| Stock Based Compensation | $26,658,000 | $39,463,000 | $42,798,000 | $46,146,000 |
| Asset Impairment Charge | $2,922,000 | $2,205,000 | $0 | $0 |
| Amortization Of Securities | $-6,579,000 | $-14,379,000 | $-15,318,000 | $-1,163,000 |
| Depreciation Amortization Depletion | $9,661,000 | $8,841,000 | $8,848,000 | $8,472,000 |
| Depreciation And Amortization | $9,661,000 | $8,841,000 | $8,848,000 | $8,472,000 |
| Depreciation | $9,661,000 | $8,841,000 | $8,848,000 | $8,472,000 |
| Net Income From Continuing Operations | $-142,929,000 | $-119,049,000 | $-130,391,000 | $-133,310,000 |
| Change In Receivables | - | $0 | $2,587,000 | $4,804,000 |
| Gain Loss On Sale Of PPE | - | $0 | $48,000 | $0 |
Fetched: 2026-05-23